ArticleInvestigational new drugs2021

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Alexey V Danilov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.